Form 8-K - Current report:
SEC Accession No. 0001104659-25-060784
Filing Date
2025-06-20
Accepted
2025-06-20 06:01:32
Documents
13
Period of Report
2025-06-19
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2518347d1_8k.htm   iXBRL 8-K 25424
2 EXHIBIT 99.1 tm2518347d1_ex99-1.htm EX-99.1 9247
  Complete submission text file 0001104659-25-060784.txt   205178

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA anvs-20250619.xsd EX-101.SCH 3020
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20250619_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20250619_pre.xml EX-101.PRE 22362
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2518347d1_8k_htm.xml XML 3790
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 251058917
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)